Newest GLP-1 Drugs (2026): Foundayo, Recently Approved & Pipeline Launches in Order

The single biggest GLP-1 news of 2026 is the April 1, 2026 FDA approval of Foundayo (orforglipron, Eli Lilly) — the first oral, non-peptide GLP-1 receptor agonist ever approved for chronic weight management [1]. Layer underneath that headline: in February 2026 the FDA finalized the removal of the suicidal-behavior-and-ideation warning from the Wegovy / Saxenda / Zepbound labels after pooling 91 placebo-controlled trials in 107,910 patients [2, 3]. In late 2025 two key phase 3 readouts landed (TRIUMPH-4 for retatrutide; SYNCHRONIZE-1 for survodutide) [6]. And across 2024-2025, three generic GLP-1s reached the US market for the first time in the class's history — Hikma liraglutide (December 2024), Amneal exenatide (November 21, 2024), and the watershed Teva liraglutide 3 mg for weight management (August 27, 2025) [4, 5]. This article walks through every dated event, anchors each to its FDA letter, DailyMed label, or manufacturer investor release, and applies an explicit hedge to every pipeline projection because manufacturer-stated FDA action dates routinely shift on patent-term extensions, paragraph-IV litigation, and 30-month stays.

April 2026: Foundayo — first small-molecule oral GLP-1 for weight management

On April 1, 2026, the FDA approved Foundayo (orforglipron, Eli Lilly LY3502970) for chronic weight management in adults with BMI ≥ 30 (obesity), or BMI ≥ 27 with at least one weight-related comorbidity [1]. Foundayo is the first non-peptide, small-molecule GLP-1 receptor agonist ever approved for any indication. Every previously FDA-approved GLP-1 RA — semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide — is a peptide. Peptides get digested in the stomach, which is why every previously approved GLP-1 is either injected (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Victoza, Trulicity) or, in the single oral case (Rybelsus), formulated with the SNAC absorption enhancer and bound to a strict fasted- morning food restriction.

Orforglipron is a small organic molecule that binds and activates the GLP-1 receptor directly. Because it's a small molecule, it survives stomach acid and digestion, does not require a fasting window, and can be taken with or without food at any time of day per the §2 dosage and administration section of the Foundayo label [1]. The practical consequences:

• Once-daily oral tablet with no refrigeration, no sharps container, no injection technique training, no cold-chain shipping logistics.
• No water cap, no fasted-morning rule. Rybelsus§2 still requires take-30-minutes-before-first- food-with-no-more-than-4-ounces-of-plain-water; Foundayo §2 says “with or without food.”
• Six-step dose ladder: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, with at least 30 days at each step before escalation [1].
• Strong CYP3A4 inhibitor dose cap. Foundayo is metabolized primarily by CYP3A4. When a strong CYP3A4 inhibitor (clarithromycin, itraconazole, ketoconazole, ritonavir-boosted antivirals) is co-administered, the §7 prescribing information caps Foundayo at 9 mg once daily — a labeled DDI unique to Foundayo in the GLP-1 weight-management class.
• ATTAIN-1 phase 3 efficacy at the FDA-approved 17.2 mg labeled max: −11.1% body weight at 72 weeks (Wharton et al., NEJM 2025, PMID 40960239) [1]. The paper reports that same arm as 36 mg of the trial formulation, with −12.4% on the efficacy estimand and −11.2% on the treatment-regimen estimand. No 36 mg tablet is sold; the label's 17.2 mg tablet is the equivalent dose.

Launch pricing. Foundayo launched on LillyDirect with shipping beginning April 6, 2026, at a self-pay floor of $149/month for the lowest-dose strength and a $25/month commercial-insurance copay for patients whose plans cover Foundayo with the manufacturer savings card [1]. Amazon Pharmacy began listing Foundayo at $149/month later in April 2026. Some telehealth services now list it too; Maximus offers Foundayo among its brand-name options. The $149 cash-pay floor is roughly an order of magnitude below the $1,300-1,400/month list pricing of Wegovy and Zepbound and is the largest single change to GLP-1 access economics since the 2021 Wegovy approval. For the live state of every cash-pay channel, see our GLP-1 pricing index. For the full Foundayo approval analysis with the ATTAIN-1 trial design, see our Foundayo FDA approval deep-dive; for the head-to-head comparison framing against injectable GLP-1s see our Foundayo vs Wegovy vs Zepbound comparison.

January-February 2026: FDA suicidality warning REMOVED from Wegovy / Saxenda / Zepbound

On January 13, 2026, the FDA issued a Drug Safety Communication finalizing its multi-year evaluation of suicidal-thoughts-or-actions reports in patients on GLP-1 receptor agonists [3]. The agency pooled 91 placebo-controlled clinical trials encompassing 107,910 patients across the approved-and-investigational GLP-1 class and concluded there was no causal association between GLP-1 RA therapy and suicidal ideation or behavior. Following the Drug Safety Communication, the FDA requested removal of the corresponding warning language from the §5 Warnings and Precautions section of the affected labels.

By February 2026 the changes had landed on the live Wegovy, Saxenda, and Zepbound labels — the “Recent Major Changes” block at the top of each DailyMed prescribing information page documents the warning removal verbatim [2]. This is one of the rare cases where an FDA post-market evaluation has resulted in a class-wide warning removal rather than an addition. The practical implications:

• The mental-health prescriber-conversation framing changes — there is no longer a labeled boxed or §5-prominent suicidality warning that a prescriber must counsel a patient on at initiation. Patient screening for active depression and prior suicide attempt remains good clinical practice but is no longer driven by a label-mandated discussion.
• The boxed warning for thyroid C-cell tumors (medullary thyroid carcinoma — MTC, MEN 2) remains unchanged on every GLP-1 RA label including Foundayo. The class-wide MTC contraindication is the most prominent label warning and is not affected by the suicidality finding.
• The label change does NOT mean GLP-1s are neutral-or-positive on every aspect of mental health. Anhedonia, emotional blunting, and reward-circuitry dampening are documented in the literature as a mechanistic class effect distinct from suicidality. For the full review of what the published evidence does and does not show on GLP-1 mood effects, see our GLP-1 mental-health, anhedonia, and emotional-blunting evidence review.

The FDA Drug Safety Communication URL [3] is the canonical primary source. Any subsequent post-market regulatory action could re-introduce a suicidality warning if new signal emerges, so prescribers should re-verify the live label at the start of each new patient relationship rather than rely on a historical reading. For the live state of Wegovy§5 see DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b [2].

Late 2025: TRIUMPH-4 (retatrutide) + SYNCHRONIZE-1 (survodutide)

Two phase 3 GLP-1-class readouts in the second half of 2025 set the stage for the 2026-2028 approval pipeline.

December 11, 2025: TRIUMPH-4 (retatrutide + obesity + knee OA)

On December 11, 2025, Eli Lilly announced topline results from TRIUMPH-4 — the phase 3 trial of retatrutide (LY3437943) in adults with obesity and knee osteoarthritis [6]. Retatrutide is a triple agonist of the GIP, GLP-1, and glucagon receptors — the only triple agonist in late-stage development. The headline Lilly investor result:

• Mean weight loss of 28.7% (71.2 lbs) at the 12 mg dose at 68 weeks (efficacy estimand) — at the time, the largest weight-loss number reported in a phase 3 anti-obesity trial.
• Statistically significant improvement in knee OA pain versus placebo. This is the first time a GLP-1-class drug has formally demonstrated superiority on an OA pain endpoint in a phase 3 program.
• Adverse events qualitatively consistent with the GLP-1 class — predominantly GI (nausea, vomiting, diarrhea, constipation), generally dose-dependent.

TRIUMPH-4 is one of several phase 3 trials in the retatrutide TRIUMPH program. TRIUMPH-1 (retatrutide in obesity without T2D) has since been published in NEJM, with 23.7% (9 mg) and 25.0% (12 mg) mean weight loss at 80 weeks versus 3.9% on placebo,^[7] and TRIUMPH-2 (retatrutide in obesity with T2D) in The Lancet, with 16.8% and 18.8% versus 5.1%.^[8] TRIUMPH-3 studies retatrutide in people with obesity and established cardiovascular disease. Lilly's August 2026 earnings release says the clinical data package is complete and that it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027.^[9] For the full mechanistic and trial-design review, see our retatrutide triple-agonist evidence review; for the manufacturer-stated approval timeline see our retatrutide approval and access timeline.

December 2, 2025: SYNCHRONIZE-1 (survodutide + obesity)

On December 2, 2025, Boehringer Ingelheim and Zealand Pharma announced topline results from SYNCHRONIZE-1 — the phase 3 trial of survodutide (BI 456906), a dual GLP-1 / glucagon receptor agonist, in adults with obesity without type 2 diabetes. Survodutide is the only late-stage dual GLP-1 / glucagon agonist in the class and is being co-developed by Boehringer Ingelheim with Zealand Pharma. Per the Boehringer investor release, SYNCHRONIZE-1 met its primary weight-loss endpoint with a magnitude in the published phase 2 range. The full SYNCHRONIZE program includes additional trials in obesity with T2D (SYNCHRONIZE-2), in adolescents (SYNCHRONIZE-Teens), and in MASH (the MASH-focused phase 3 trial). For the broader survodutide / MariTide / ecnoglutide pipeline framing see our GLP-1 pipeline review.

2024-2025: First three generic GLP-1s FDA-approved

Three generic GLP-1 receptor agonists reached the US market in 2024-2025 — the first generics in the class's history.

December 2024: Hikma generic liraglutide (referencing Victoza) — FIRST generic GLP-1 RA in US history

In December 2024 the FDA approved Hikma Pharmaceuticals' generic liraglutide injection referencing Novo Nordisk's Victoza (liraglutide 1.8 mg max for type 2 diabetes) [4]. This was the first FDA-approved generic GLP-1 receptor agonist in US history. The approval pathway was a small-molecule ANDA (Abbreviated New Drug Application) — Victoza was filed under an NDA in 2010, so the post-loss-of- exclusivity competition pathway is the standard bioequivalence-anchored ANDA, not the 351(k) biosimilar pathway. Generic liraglutide for T2D is NOT approved for chronic weight management — the weight-management indication required a separate ANDA referencing Saxenda (the 3 mg dose).

November 21, 2024: Amneal generic exenatide (referencing Byetta)

On November 21, 2024, the FDA approved Amneal Pharmaceuticals' generic exenatide referencing AstraZeneca's Byetta (exenatide twice-daily). The Amneal generic exenatide approval came just weeks after AstraZeneca's October 2024 discontinuation of Byetta (October 25, 2024) and Bydureon BCise (October 28, 2024), so the practical market access for generic exenatide has been limited — most clinicians transitioned T2D patients to once-weekly tirzepatide or semaglutide instead of switching to a generic twice-daily exenatide.

August 27, 2025: Teva generic liraglutide 3 mg (referencing Saxenda) — FIRST generic GLP-1 RA for chronic weight management

On August 27, 2025, the FDA approved Teva Pharmaceuticals' authorized generic liraglutide 3 mg, referencing Novo Nordisk's Saxenda [5]. This was the first generic GLP-1 RA approved for chronic weight management — a watershed moment for cash-pay obesity-medication access because Saxenda's pre-generic list price ran $1,300-1,500/month. The Teva generic launched at a materially lower wholesale acquisition cost; sustained retail-pharmacy availability has been pharmacy-channel and benefit-design dependent through 2026.

Why this matters: NDA pathway vs BLA pathway

Every FDA-approved GLP-1 RA except Trulicity (dulaglutide, Eli Lilly) was filed under a New Drug Application (NDA) — small-molecule (or peptide-classed-as- small-molecule) regulatory dossier. The post-LOE pathway is the small-molecule ANDA generic, which is what the Hikma, Teva, and Amneal generic approvals walked through. Trulicity is a biologic — an Fc-fusion biologic where a modified GLP-1 peptide sequence is fused to a human IgG4 Fc fragment to extend its half-life for once-weekly dosing — and was filed under a Biologic License Application (BLA). The post-LOE pathway for Trulicity is therefore a 351(k) biosimilar, with substantially higher dossier costs (typically $100M+ versus $5-20M for an ANDA), longer clearance times, and fewer manufacturers willing to invest. As of May 2026, no biosimilar dulaglutide is FDA-approved. Foundayo (orforglipron) is the only actual non-peptide small molecule in the class and will follow the small-molecule ANDA pathway after its loss of exclusivity. For the full BLA-vs-NDA explainer, see our GLP-1 medication list.

Other 2024-2025 events worth flagging

• October 2024: FDA enforcement-discretion period ENDED for compounded semaglutide and tirzepatide. The two-year period during which 503A and 503B compounding pharmacies could legally compound and dispense semaglutide and tirzepatide while the FDA-listed shortages persisted finished in October 2024 (semaglutide) and February 2025 (tirzepatide) per FDA notices. Compounded GLP-1s post- October 2024 are regulatory gray-zone for any patient not meeting the FDA's narrow clinical-need exemptions — they are NOT generics and are not equivalent to the FDA-approved Hikma, Amneal, or Teva generic GLP-1s above. For the FDA warning-letter enforcement landscape against telehealth providers offering compounded GLP-1s, see our FDA warning letters investigation.
• October 25, 2024: AstraZeneca DISCONTINUED Byetta (exenatide twice-daily) on the US market.
• October 28, 2024: AstraZeneca DISCONTINUED Bydureon BCise (exenatide extended-release once-weekly).
• January 2025: REDEFINE-2 (CagriSema in T2D + obesity) reached primary completion. This is the T2D-population arm of the broader Novo Nordisk REDEFINE phase 3 program for CagriSema (semaglutide + cagrilintide fixed-ratio).
• October 17, 2025: Rybelsus (oral semaglutide) cardiovascular indication was added to the label per the SOUL trial. The CV indication is limited to the 7 mg and 14 mg doses — the 25 mg dose is not included in the SOUL CV indication. Rybelsus remains FDA-approved for type 2 diabetes ONLY and is NOT FDA-approved for weight management.

2026 events on the live GLP-1 timeline

Three additional 2026 events are worth noting alongside the Foundayo approval and the Wegovy / Saxenda / Zepbound suicidality-warning removal documented above.

• March 2026: Sciwind Biosciences' ecnoglutide (XW003) was approved by the China NMPA for chronic weight management. Ecnoglutide is a long-acting GLP-1 receptor agonist developed in China; It has NOT received FDA approval and cannot be bought in the US. See the “China-only approvals” section below for why an NMPA approval should not be read as predicting FDA approval.
• April 1, 2026: Foundayo (orforglipron, Eli Lilly) FDA-approved for chronic weight management — first small-molecule (non-peptide) oral GLP-1 RA for weight management.
• April 2026: Amazon Pharmacy launched Foundayo at $149/month, broadening cash-pay distribution beyond LillyDirect.

What's coming 2026-2028 (manufacturer guidance — hedge applied)

Pipeline timelines below are manufacturer-stated guidance, not FDA commitments. Patent-term extensions, paragraph-IV ANDA challenges, 30-month stays, FDA refuse-to-file letters, complete-response letters (CRLs), REMS attachments, and advisory-committee adverse votes can each shift these dates by quarters or years. Nothing below is a prescriber decision or an investment thesis.

The biggest single uncertainty: retatrutide . TRIUMPH-1 and TRIUMPH-2 are now published,^[7][8] and Lilly's August 2026 earnings release says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.^[9] The FDA action date then depends on the length and outcome of the FDA's review, which Lilly has not projected in that filing. Any approval date you see for retatrutide is an estimate until the FDA issues its decision. For the live trial-by-trial state see our retatrutide approval and access timeline and the GLP-1 pipeline tracker.

Investigational GLP-1-class drugs in late-stage trials

Below are the major investigational GLP-1-class compounds in late-stage development as of May 2026. None of these is FDA-approved. Buying or self-administering them outside a clinical trial is illegal in the US and carries unverified-purity, unverified-potency, and unverified-contamination risk.

• Retatrutide (Eli Lilly LY3437943) — triple agonist (GIP/GLP-1/glucagon). Phase 3 TRIUMPH program. NOT FDA-approved.
• MariTide / maridebart cafraglutide (Amgen) — GLP-1 receptor agonist conjugated to a GIP receptor antagonist, dosed monthly. Phase 3 MARITIME-1 + MARITIME-2 (primary completion January 21, 2027). NOT FDA-approved.
• CagriSema (Novo Nordisk) — fixed-ratio combination of semaglutide (GLP-1 RA) and cagrilintide (long-acting amylin analog). Phase 3 REDEFINE program — REDEFINE-1 + REDEFINE-2 readouts complete; REDEFINE-3 (CVOT) primary completion September 1, 2027. NOT FDA-approved. For the trial-by-trial breakdown see our CagriSema REDEFINE trial results review.
• Survodutide (Boehringer Ingelheim + Zealand Pharma BI 456906) — dual GLP-1 / glucagon receptor agonist. SYNCHRONIZE-1 completed Dec 2 2025. NOT FDA-approved.
• Mazdutide (Innovent + Eli Lilly IBI362) — dual GLP-1 / glucagon receptor agonist. Approved by China NMPA in 2025 for type 2 diabetes; no FDA filing as of May 2026. NOT FDA-approved.
• Ecnoglutide (Sciwind XW003) — long- acting GLP-1 receptor agonist. Approved by China NMPA in March 2026 for chronic weight management; no FDA filing as of May 2026. NOT FDA-approved.
• Pemvidutide (Altimmune ALT-801) — dual GLP-1 / glucagon receptor agonist. Phase 2 MOMENTUM in obesity; FDA Fast Track in MASH. NOT FDA-approved.
• Petrelintide (Zealand Pharma + Roche) — long-acting amylin analog (not technically a GLP-1 RA, but co-developed alongside the class and frequently discussed in the same patient queries). Phase 2 ZUPREME-1 complete. NOT FDA-approved.

For the depth-tracker view of every NCT ID, primary completion date, and topline result for each investigational drug above, see our GLP-1 pipeline tracker.

China-only approvals (NOT FDA-approved)

Two GLP-1-class drugs have been approved by the China National Medical Products Administration (NMPA) but are NOT FDA-approved and are NOT on the US market.

• Mazdutide (Innovent + Eli Lilly IBI362) — China NMPA approved in 2025 for type 2 diabetes.
• Ecnoglutide (Sciwind XW003) — China NMPA approved March 2026 for chronic weight management.

A China NMPA approval does NOT predict FDA approval and does NOT make a drug available in the United States. The NMPA and FDA are independent regulatory agencies with different filing dossiers, different bridging-trial requirements, and different timelines. Drugs approved by the NMPA and not the FDA are not legally importable for personal use; the FDA personal-importation policy does not apply to chronic prescription drugs available on the US market in a different formulation. Patients should not confuse a Chinese-pharmacy ecnoglutide or mazdutide listing with an FDA-approved alternative to Wegovy, Zepbound, Saxenda, or Foundayo.

How to track upcoming readouts

The cleanest way to track this class is to read the primary sources directly: ClinicalTrials.gov for trial primary-completion dates and design changes; Drugs@FDA for FDA approval letters and labeling-change supplements; DailyMed for the live FDA prescribing information; the FDA Drug Safety Communication archive for post-market signal evaluations; and the manufacturer investor-relations pages (Lilly, Novo Nordisk, Amgen, Boehringer Ingelheim, Zealand Pharma, Innovent, Sciwind, Altimmune) for trial topline results before they hit the peer-reviewed literature. For the consolidated trial-tracker view across the entire GLP-1 class — every NCT ID, every primary completion date, every topline result, every NDA filing — see our GLP-1 pipeline tracker (2026). For the drug-by-drug FDA-label reference list, see our full GLP-1 medication list.

Bottom line

The single biggest 2026 event was the April 1, 2026 FDA approval of Foundayo (orforglipron) — the first oral non-peptide GLP-1 RA for chronic weight management, launched at a $149/month cash- pay floor on LillyDirect and Amazon Pharmacy. The FDA Drug Safety Communication of January 13, 2026 — and the February 2026 follow-on label changes — removed the suicidal-behavior-and-ideation warning from Wegovy, Saxenda, and Zepbound after pooling 91 placebo-controlled trials in 107,910 patients. Three generic GLP-1s reached the US market across 2024-2025 — Hikma liraglutide, Amneal exenatide, and the watershed Teva liraglutide 3 mg for weight management. Late 2025 phase 3 readouts (TRIUMPH-4 retatrutide, SYNCHRONIZE-1 survodutide) set the stage for the 2026-2028 approval pipeline. Pipeline dates are manufacturer-stated guidance and shift on patent-term extensions, paragraph-IV litigation, FDA refuse-to-file letters, and 30-month stays — every projected date in this article should be re-verified against the live FDA Drugs@FDA page and the manufacturer investor-relations page before any clinical decision or patient counseling.